<DOC>
	<DOC>NCT01473836</DOC>
	<brief_summary>The purpose of this study is to evaluate the clinical efficacy and safety in Japanese adult subjects with Intra-abdominal/Pelvic infections receiving Metronidazole IV 1,500-2,000 mg/day in combination with ceftriaxone sodium.</brief_summary>
	<brief_title>A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>16 years of age or older. Diagnosed with intraabdominal infections or pelvic inflammatory diseases. Can be obtained a specimen for bacteriological efficacy assessment. Known or suspected hypersensitivity, intolerance or contraindication to Metronidazole, Ceftriaxone sodium, or other cephem antibiotics. Severe renal dysfunction (creatinine clearance &lt; 30 mL/min.) Reference: CockcroftGault calculation formula. Hepatic dysfunction (AST, ALT, total bilirubin &gt; 3 times upper limit of normal range values). Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Metronidazole</keyword>
	<keyword>intra-abdominal infection</keyword>
	<keyword>pelvic inflammatory disease</keyword>
	<keyword>anaerobe</keyword>
</DOC>